Items tagged with Medicines
New inhibitors may offer novel approach to treating deadly TB (post)
WEST LAFAYETTE, Ind. – Purdue University innovators have developed highly potent and selective compounds for use in the treatment of tuberculosis, which is one of the top 10 causes of death worldwide.
BioVersys receives €20 million in EU financing to support development of new antibiotics (post)
-- European Investment Bank and BioVersys sign a financing agreement of up to €20 million to facilitate the development of new treatments against life-threatening resistant bacterial infections.
-- The venture debt loan is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the European Union’s research and innovation programme for 2014-2020.
-- BioVersys has a rich pipeline of drugs in clinical development for the treatment of tuberculosis and hospital-acquired infections, like ventilator-associated pneumonia, seen most recently in COVID-19 patients in intensive care. The company has additional preclinical assets and follow-on programmes all focusing on different unmet medical needs in antimicrobial resistance.
Praedicare Inc. receives grant to evaluate potential new drug regimens for TB (post)
DALLAS, June 17, 2021 -- Praedicare Inc., a CRO using unique pre-clinical laboratory and proprietary mathematical translation models today announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel TB drug regimens using Praedicare’s in vitro hollow fiber model of tuberculosis (TB) in identifying potential new drug regimens that shorten treatment times for the disease.
Common antibiotic found useful in accelerating recovery in TB patients (post)
Researchers have discovered that the use of a common antibiotic, doxycycline, in combination with TB drug treatment, reduces the size of lung cavities and accelerates markers of lung recovery. This was done in a trial with 30 pulmonary TB patients.
Active TB Drug Safety Monitoring and Management (aDSM) global database: Outcome of the assessment and future of data reporting (post)
6 July 2021, Geneva | A global database set up by WHO’s Global Tuberculosis Programme in collaboration with the Special Programme for Research and Training in Tropical Diseases (TDR) has been collating data on Active TB Drug Safety Monitoring and Management (aDSM) since 2016, to monitor the safety of patients who receive MDR-TB treatment with new medicines (e.g. bedaquiline, delamanid), repurposed medicines (e.g. linezolid, clofazimine) or new regimens, which don't have a well-established safety profile. The aDSM framework has been promoted by WHO and stakeholders since 2015 for monitoring safety for patients who receive MDR-TB treatment with medicines of interest and successfully implemented in many countries for ensuring safety of patients while rolling of the newly recommended MDR-TB treatment regimens.
Launch of UNITE4TB partnership marks a new era in TB treatment development (post)
The partnership will accelerate the development of new TB drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research & Development Consortium.
WHO position statement on innovative clinical trial designs for development of new TB treatments (post)
The World Health Organization (WHO) is publishing a position statement on Innovative Clinical Trial Designs for Development of New TB Treatments. This document aims to support TB regimen development by highlighting key clinical trial characteristics to help advance novel therapies. It summarises key innovations in TB clinical trial designs, ranging from pharmacokinetic-pharmacodynamic (PK-PD) modelling and new advances in biomarker development to the value of novel clinical trial design methodologies and post-licensure observational studies.
CHMP grants positive opinion for Otsuka’s child-friendly 25 mg dispersible tablet formulation of Deltyba (post)
CHMP grants positive opinion in the European Union for Otsuka’s child-friendly 25 mg dispersible tablet formulation of Deltyba® (delamanid) for the paediatric population weighing at least 10 kg with pulmonary multidrug-resistant TB
What’s new in the TB section of the 2021 WHO Model Lists of Essential Medicines (post)
24 November 2021 | Geneva -- The World Health Organization’s (WHO’s) 2021 Model Lists of Essential Medicines feature key updates to the TB section including the addition of moxifloxacin and rifapentine for the indication of drug susceptible TB, child friendly formulations of bedaquiline and delamanid to treat drug resistant TB and a higher dose formulation of rifapentine for TB preventive treatment. Further updates include the addition of other TB medicines to the list as well as the removal of some TB medicines that are no longer considered essential. The revised list provides a comprehensive list of quality assured TB medicines for TB preventive treatment as well as for the treatment of drug susceptible and drug resistant TB.
RESIST-TB webinar: Pediatric PK for the new and repurposed TB drugs – Where are we now? (post)
RESIST-TB will host a webinar on the latest developments in pediatric pharmacokinetics (PK) of bedaquiline, linezolid, delamanid and pretomanid on 26 January 2022.
Page 12 of 19 · Total posts: 0
←First 11 12 13 Last→